Research this topic
Explore the main themes, entities and connections around Copanlisib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Explore this topic
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
History
Adverse effects
Society and culture
Mechanism of action
Key facts & relationships
High-confidence facts extracted from structured source data. Use them as anchors for further research.
- 3D model (JSmol)
- Interactive image
- AHFS/Drugs.com
- Monograph
- ATC code
- L01EM02 (WHO)
- CAS Number
- 1032568-63-0
- ChEBI
- CHEBI:173077
- ChEMBL
- ChEMBL3218576
Topics to explore
A structured outline of related entities, concepts and subtopics. Open any item to build a new map centered on it.Browse the full topic structure. Each item opens a new analysis centered on that subject.
Overview
Adverse effects
Mechanism of action
- Phosphatidylinositol-3-kinase Phosphoinositide 3-kinase
- PI3K-α P110α
- PI3K-δ P110δ
- Apoptosis
History
Society and culture
Advanced semantic analysis
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
Map overview Semantic statistics
Number of nodes, edges, triples, density and central hubs. Use it to gauge the size and connectivity of the map.Copanlisib
How this topic connects Entity context
Quick relationship hints grouped by predicate. Useful for spotting recurring semantic connections around the current entity.See the strongest relationship patterns around the current topic before diving into the raw triples.
Copanlisib
Top relations
Important terminology Word statistics
Frequent words and multi-word phrases across the lead, headings, infobox and body. Useful for terminology coverage.Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
Important terminology
lymphoma follicular drug treatment clinical trials status phase adults relapsed two fda effects data name aliqopa us legal trial cancer
Entity relationships Subject–Predicate–Object triples
Extracted RDF-like relationships with confidence and source. The table includes structured facts and lower-confidence contextual relations.| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Copanlisib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Copanlisib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Copanlisib | ATC code | L01EM02 (WHO) | 1.00 | infobox |
| Copanlisib | CAS Number | 1032568-63-0 | 1.00 | infobox |
| Copanlisib | ChEBI | CHEBI:173077 | 1.00 | infobox |
| Copanlisib | ChEMBL | ChEMBL3218576 | 1.00 | infobox |
| Copanlisib | ChemSpider | 25069683 | 1.00 | infobox |
| Copanlisib | CompTox Dashboard (EPA) | DTXSID00145728 | 1.00 | infobox |
| Copanlisib | Drug class | PI3-Kinase inhibitor | 1.00 | infobox |
| Copanlisib | DrugBank | DB12483 | 1.00 | infobox |
| Copanlisib | Elimination half-life | 39.1 hours (range: 14.6 to 82.4) | 1.00 | infobox |
| Copanlisib | Excretion | Feces (64%), Urine (22%); 14% were not recovered | 1.00 | infobox |
| Copanlisib | Formula | C23H28N8O4 | 1.00 | infobox |
| Copanlisib | KEGG | D10867 | 1.00 | infobox |
| Copanlisib | Legal status | US: ℞-only | 1.00 | infobox |
| Copanlisib | License data | US DailyMed: Copanlisib | 1.00 | infobox |
| Copanlisib | License data | US FDA: 209936 | 1.00 | infobox |
| Copanlisib | MedlinePlus | a617044 | 1.00 | infobox |
| Copanlisib | Metabolism | CYP3A4/5 (≈90%), CYP1A1 (≈10%) | 1.00 | infobox |
| Copanlisib | Molar mass | 480.529 g·mol−1 | 1.00 | infobox |
| Copanlisib | Other names | BAY 80-6946 | 1.00 | infobox |
| Copanlisib | Protein binding | 84.2% | 1.00 | infobox |
| Copanlisib | PubChem CID | 24989044 | 1.00 | infobox |
| Copanlisib | Routes of administration | Intravenous | 1.00 | infobox |
| Copanlisib | Trade names | Aliqopa | 1.00 | infobox |
| Copanlisib | UNII | WI6V529FZ9 | 1.00 | infobox |
Related concept clusters Concept neighborhoods
Clusters of nearby vocabulary surrounding the topic. Scan them for adjacent concepts and language you may have missed.These clusters group vocabulary that occurs around closely connected concepts in the source material.
Connections between topic areas Semantic bridges
Bridge nodes connect otherwise separate parts of the map. Expand a row to inspect the topic groups on each side.Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.